25,975 Celcuity, Inc. $CELC Shares Acquired by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. increased its holdings in Celcuity, Inc. (NASDAQ:CELC) by 33.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,775 shares of the company’s stock after buying an additional 25,975 shares during the period. Nan Fung Trinity HK Ltd. owned about 0.21% of Celcuity worth $8,252,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Parallel Advisors LLC purchased a new position in Celcuity during the 1st quarter valued at about $38,000. PNC Financial Services Group Inc. lifted its holdings in shares of Celcuity by 20.1% in the first quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after purchasing an additional 86 shares in the last quarter. KBC Group NV purchased a new stake in shares of Celcuity in the first quarter valued at about $64,000. IFP Advisors Inc acquired a new stake in shares of Celcuity in the second quarter valued at approximately $73,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Celcuity by 139.1% in the first quarter. EverSource Wealth Advisors LLC now owns 820 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares during the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity Stock Down 0.2%

NASDAQ:CELC opened at $64.17 on Friday. Celcuity, Inc. has a 12-month low of $53.54 and a 12-month high of $151.02. The company’s 50-day moving average is $73.11 and its two-hundred day moving average is $98.49. The company has a debt-to-equity ratio of 6.04, a quick ratio of 8.93 and a current ratio of 14.62.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.51) by $0.30. Research analysts expect that Celcuity, Inc. will post -5.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CELC. Guggenheim started coverage on shares of Celcuity in a research note on Friday, November 6th. They set a “buy” rating and a $169.00 price objective for the company. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research note on Monday. Zacks Research cut Celcuity from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Wall Street Zen cut Celcuity from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Stifel Nicolaus dropped their price target on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $151.79.

Celcuity Profile

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.